Results 131 to 140 of about 104,823 (289)
, 2011 Miki Gondo1, Tsutomu Sakai1, Hiroshi Tsuneoka1, Chihiro Kanehira21Department of Ophthalmology, Jikei University School of Medicine, 2Division of Radiology, Jikei University School of Medicine, Tokyo, JapanBackground: The evaluation of intravitreal ...
Sakai T +7 more
core +1 more source
The Journal of Pathology, EarlyView.Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related deaths globally, and cases are predicted to rise dramatically over the next few years. Overcoming the immune microenvironment in HCC remains a challenge, and innate immune populations such as tumour‐associated neutrophils can potentially impair the success of immunotherapy ...
Joanne M O'Rourke +24 more
wiley +1 more source
Pediatric spinal ependymomas: Long‐term surgical outcomes in a cohort of 61 cases
Pediatric Investigation, EarlyView.Spinal ependymomas are rare in children, with limited long‐term outcome data. In this retrospective study of 61 pediatric patients undergoing surgical resection, gross total resection was achieved in 62.3% and was associated with favorable functional improvement. Recurrence was observed in 31.1% of cases.
Liang Zhang +3 more
wiley +1 more source
A new perspective on radiotherapy in the comprehensive treatment of cancer
Precision Radiation Oncology, EarlyView.Radiotherapy remains a key component in the comprehensive management of cancer. Its effectiveness is significantly improved through strategic combinations with chemotherapy, targeted therapy, and immunotherapy, providing a range of therapeutic outcomes from cure to palliative care.
Yingze Ma +4 more
wiley +1 more source
Bevacizumab in the treatment of HER2-negative breast cancer
, 2008 Vito LorussoOncologic Institute, Vito Fazzi Hospital, Lecce, ItalyAbstract: Angiogenesis has a clear and definite role in the breast cancer progression process, making antivascular endothelial growth factor (VEGF) therapies an attractive option for the ...
Vito Lorusso
core
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar +5 more
wiley +1 more source
Critical appraisal of bevacizumab in the treatment of ovarian cancer
, 2015 Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, JapanAbstract: Bevacizumab is the first molecular-targeted agent to be used for the treatment of
Fujiwara K, Yabuno A, Yoshida H
core
, 2008 Objectives: To identify the expected delay between publication of conference abstracts and full publication of results from trials of new anti-cancer agents for breast cancer and to identify whether there are any apparent biases in publication and ...
Hartwell, D. +9 more
core +1 more source
Recent progress on the development of hydrogel‐based microneedles for transdermal drug delivery
VIEW, EarlyView.This study provides a comprehensive and up‐to‐date analysis of recent progress in HMN technology, covering fundamental transdermal delivery mechanisms and design principles, biomaterials used in HMN fabrication, drug loading and release strategies, and emerging therapeutic applications.
Mohammad Muhtasim Ittisaf +5 more
wiley +1 more source
Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia
, 2016 Objectives: To evaluate the efficacy of intravitreal bevacizumab treatment in type 2 idiopathic macular telangiectasia (IMT). Materials and Methods: Six eyes of 5 patients with type 2 IMT who received intravitreal bevacizumab between 2009 and 2014 were ...
Gürkan Erdoğan +3 more
core +1 more source